ozempic semaglutide (semaglutide) for the Treatment of Type 2 Diabetes OZEMPIC (semaglutide) injection - South

It is a small-molecule oral GLP-1 receptor agonist developed by Eli Lilly, the same company behind tirzepatide

In controlled clinical trials of metformin of 29 weeks duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels was observed in approximately 7% of patients

doi:10.1177/2042018815618177 146

Still, some people might experience some discomfort , such as pain, bruising, redness, or temporary irritation at the injection site immediately after injection

Nausea, bloating, and constipation can worsen temporarily, making it crucial to distinguish medication side effects from disease flares

The SURMOUNT-5 trial , as described by Aronne and colleagues, compared tirzepatide (Zepbound) to semaglutide (Wegovy), a mono GLP-1, in 751 adults living with obesity with one weight-related medical issue but without diabetes